LCTX News and Press, BioTime Inc. From 04/29/24

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss. Mr. Kingsley served as Chairman of ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development...

Event Scheduled for June 26 and 27, 2024 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organizati...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT0...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG650...

2024-03-07 22:22:17 ET Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Conference Call March 07, 2024, 04:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - CFO Conference Call Participants Joe Pantginis - H.C...

2024-03-07 16:09:45 ET More on Lineage Cell Therapeutics Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell Therapeutics Financial informat...

Advanced OpRegen ® For Dry AMD in Phase 2a Study in Collaboration with Roche and Genentech Closed $14 Million Registered Direct Offering OPC1 Investigational New Drug Amendment Cleared; New Clinical Trial Planned Initiated Development of Hypoimmune iPSC Cell Line ...

2024-03-06 17:35:34 ET More on Lineage Cell Therapeutics Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell Therapeutics Financial informat...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 20...